Back to search
FDAFDA · Food and drugs·Recall number D-0285-2024

Rifampin Capsules USP, 150 mg, 30 Capsules (3 x 10) unit doses per carton, Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217. NDC Carton: 60687-575-21; NDC Unit Dose: 60687-575-11

Published February 7, 2024 · Recall initiated: January 11, 2024

Summary

FDA records drug Class II recall D-0285-2024, published February 7, 2024 and initiated January 11, 2024. Recalling firm: Amerisource Health Services LLC; Status: Terminated; Reported quantity: 1,568 cartons; Lot: Lot #: 1008111, Exp. Date 01/31/2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specification.

What to do

Voluntary: Firm initiated · Letter

Get an email if RIFAMPIN has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
RIFAMPIN
Manufacturer
Amerisource Health Services LLC
Distributor
Nationwide in the USA
Lot
Lot #: 1008111, Exp. Date 01/31/2024
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Rifampin Capsules USP, 150 mg, 30 Capsules (3 x 10) unit doses per carton, Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217. NDC Carton: 60687-575-21; NDC Unit Dose: 60687-575-11 recalled?

Yes. FDA published recall D-0285-2024 on February 7, 2024. Reported hazard: Failed Impurities/Degradation Specification.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: RIFAMPIN.